trauma-care
(2)
Cayuga Biotech
Cayuga Biotech is a clinical-stage biotech developing first-in-class therapeutics that stop life-threatening bleeding by accelerating the body's own clotting cascade. Its lead candidate, CAY001, is a synthetic polyphosphate-silica nanoparticle (polyP-SNP) designed to work where conventional hemostatic agents fall short - non-compressible hemorrhage from trauma, surgery, blood thinners and inherited bleeding disorders. Founded on research from UC Santa Barbara, the company harnesses polyphosphate, a natural cofactor stored in platelets, to normalize thrombin production and speed clot formation without slowing clot breakdown.
Abram Scientific
Abram Scientific is a Menlo Park, California medical-device company building CoagCare, a portable point-of-care platform that reads the full blood-coagulation cascade - from clot formation through fibrinolysis - from a single drop of blood in under 10 minutes. By measuring blood viscoelasticity and density on single-use test cards inside a vibration-insensitive handheld meter, CoagCare aims to move coagulation testing out of the central lab and into trauma bays, ambulances, and MEDEVAC helicopters, helping clinicians decide the right transfusion or therapy at the right time.